Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.
low-dose-rate brachytherapy
prostate cancer
quality of life
α-1 adrenoceptor antagonists
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
20
10
2020
accepted:
19
07
2021
pubmed:
12
8
2021
medline:
6
11
2021
entrez:
11
8
2021
Statut:
ppublish
Résumé
To compare the effects of naftopidil and silodosin administration on the quality of life of patients with prostate cancer who underwent low-dose-rate brachytherapy. In total, 141 men diagnosed with localized prostate cancer who were treated with low-dose-rate brachytherapy were enrolled. Patients were randomized (1:1) to the naftopidil (75 mg/day, n = 63) or silodosin group (8 mg/day, n = 64). Naftopidil and silodosin were administered 1 day after low-dose-rate brachytherapy, and were continued for at least 3 months. Using the University of California at Los Angeles Prostate Cancer Index and Sexual Health Inventory for Men scores, the mean changes and rates of deterioration from baseline were compared. The deterioration rates in the quality of life of patients at 1 and 3 months after low-dose-rate brachytherapy were evaluated based on the minimal important difference. The rates of deterioration from baseline to 1 and 3 months after low-dose-rate brachytherapy were not significantly different between the two groups in terms of urinary function, urinary bother, bowel bother, sexual function or Sexual Health Inventory for Men scores. In contrast, there were significant differences in bowel function (naftopidil 1 month, 52%; 3 months, 52%; silodosin 1 month, 28%; 3 months, 34%; 1 month, P < 0.01; 3 months, P = 0.048) and sexual bother (naftopidil 3 months, 11%; silodosin 3 months, 29%; P = 0.01). Naftopidil and silodosin provide different disease-specific quality of life outcomes in patients undergoing, especially in terms of bowel function and sexual bother. These findings can help in the selection of α-1 adrenoceptor antagonists after low-dose-rate brachytherapy.
Substances chimiques
Indoles
0
Naphthalenes
0
Piperazines
0
silodosin
CUZ39LUY82
naftopidil
R9PHW59SFN
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1171-1176Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Japanese Urological Association.
Références
Grimm P, Billiet I, Bostwick D et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012; 109(Suppl.1): 22-9.
Taussky D, Ouellet V, Delouya G, Saad F. A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer. Can. Urol. Assoc. J. 2016; 10: 246-50.
Kishan AU, Cook RR, Ciezki JP et al. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason Score 9-10 prostate cancer. JAMA 2018; 319: 896-905.
Morris WJ, Tyldesley S, Rodda S et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2017; 98: 275-85.
Tanaka N, Fujimoto K, Hirao Y, Asakawa I, Hasegawa M, Konishi N. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer. Urology 2009; 74: 407-11.
Miller DC, Sanda MG, Dunn RL et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J. Clin. Oncol. 2005; 23: 2772-80.
Tanaka N, Asakawa I, Anai S et al. Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy. Radiat. Oncol. 2013; 8: 25.
Merrick GS, Butler WM, Lief JH, Dorsey AT. Temporal resolution of urinary morbidity following prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2000; 47: 121-8.
Bylund DB, Eikenberg DC, Hieble JP et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 1994; 46: 121-36.
Michelotti GA, Price DT, Schwinn DA. Alpha 1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol. Ther. 2000; 88: 281-309.
Hampel C, Dolber PC, Smith MP et al. Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. J. Urol. 2002; 167: 1513-21.
Shibata K, Foglar R, Horie K et al. a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol. Pharmacol. 1995; 48: 250-8.
Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J. Pharmacol. 1999; 79: 447-54.
Tanaka N, Torimoto K, Asakawa I et al. Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil. Radiat. Oncol. 2014; 9: 302.
Scofield MA, Liu F, Abel PW, Jeffries WB. Quantification of steady state expression of mRNA for alpha-1 adrenergic receptor subtypes using reverse transcription and a competitive polymerase chain reaction. J. Pharmacol. Exp. Ther. 1995; 275: 1035-42.
Masuda M, Jinza S, Masuko H, Asakura T, Hashiba T. Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study. Hinyokika Kiyo 2012; 58: 671-8.
Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998; 36: 1002-12.
Day D, Ambegaonkar A, Harriot K, McDaniel A. A new tool for predicting erectile dysfunction. Adv. Ther. 2001; 18: 131-9.
Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 2008; 358: 1250-61.
Tsumura H, Satoh T, Ishiyama H et al. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. Int. J. Radiat. Oncol. Biol. Phys. 2011; 81: e385-92.
Ash D, Bottomley D, Al-Qaisieh B, Carey B, Gould K, Henry A. A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. Radiother. Oncol. 2007; 84: 135-9.
Vidt DG, Bakst AW, Graham RM. Adrenergic receptors: structure and function. Cleve Clin. J. Med. 1990; 57: 481-91.
Matsumoto S, Kasamo S, Hashizume K. Influence of alpha-adrenoceptor antagonists therapy on stool form in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Low. Urin. Tract Symptoms 2020; 12: 86-91.
Yokoyama T, Hara R, Fukumoto K et al. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. Int. J. Urol. 2011; 18: 225-30.
Yamaguchi K, Aoki Y, Yoshikawa T, Hachiya T, Saito T, Takahashi S. Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. Int. J. Urol. 2013; 20: 1234-8.
Nagai A, Hara R, Yokoyama T, Jo Y, Fujii T, Miyaji Y. Ejaculatory dysfunction caused by the new alpha1-blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography. Int. J. Urol. 2008; 15: 915-8.
Hisasue S, Furuya R, Itoh N, Kobayashi K, Furuya S, Tsukamoto T. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int. J. Urol. 2006; 13: 1311-6.
Capogrosso P, Serino A, Ventimiglia E et al. Effects of silodosin on sexual function - realistic picture from the everyday clinical practice. Andrology 2015; 3: 1076-81.